The Role of Mitomycin C in the Treatment of Ocular Surface Squamous Neoplasia
Journal of Ophthalmic and Optometric Sciences,
Vol. 7 No. 2 (2023),
11 July 2024
,
Page 35-40
https://doi.org/10.22037/joos.v7i2.45981
Abstract
Ocular surface tumors, arising from the squamous epithelium, melanocytes, and lymphocytic resident cells of the conjunctival stroma and cornea, present a challenge in ophthalmic oncology. Ocular surface squamous neoplasia (OSSN) encompasses a spectrum of epithelial squamous malignancies that range from mild to severe dysplasia to invasive squamous cell carcinoma. Traditionally, surgical excision has been the treatment of choice for OSSN, but Mitomycin C (MMC) has emerged as a valuable adjunctive treatment option, decreasing the recurrence rate of these tumors. This review provides an overview of the use of MMC in the management of OSSN, including dosing regimens, complications, and long-term outcomes.
- Mitomycin
- Treatment
- Ocular
- Squamous Neoplasia
How to Cite
References
- Othman IS. Ocular surface tumors. Oman J Ophthalmol. 2009;2(1):3-14.
- Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Indian J Ophthalmol. 2019;67(12):1930-48.
- Eagle RC Jr. Ocular tumors: Triumphs, challenges and controversies. Saudi J Ophthalmol. 2013;27(3):129-32.
- Nanji AA, Moon CS, Galor A, Sein J, Oellers P, Karp CL. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. Ophthalmology. 2014;121(5):994-1000.
- Hӧllhumer R, Williams S, Michelow P. Ocular surface squamous neoplasia: management and outcomes. Eye (Lond). 2021;35(6):1562-73.
- Chen C, Louis D, Dodd T, Muecke J. Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol. 2004;88(1):17-8.
- Kemp EG, Harnett AN, Chatterjee S. Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol. 2002;86(1):31-4.
- Esmaeli B, Wang X, Youssef A, Gershenwald JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001;108(11):2101-5.
- Tsatsos M, Karp CL. Modern management of ocular surface squamous neoplasia. Expert Review of Ophthalmology. 2013;8(3); 287-95.
- Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1108-14.
- Shields CL, Naseripour M, Shields JA. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol. 2002;133(5):601-6.
- Gupta A, Muecke J. Treatment of ocular surface squamous neoplasia with Mitomycin C. Br J Ophthalmol. 2010;94(5):555-8.
- Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol. 1998;82(5):476-9.
- Brouwer NJ, Verdijk RM, Heegaard S, Marinkovic M, Esmaeli B, Jager MJ. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options. Prog Retin Eye Res. 2022;86:100971.
- Blasi MA, Maceroni M, Sammarco MG, Pagliara MM. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study. Eur J Ophthalmol. 2018;28(2):204-9.
- Murthy R, Gupta H, Krishnatry R, Laskar S. Electron beam radiotherapy for the management of recurrent extensive ocular surface squamous neoplasia with orbital extension. Indian J Ophthalmol. 2015;63(8):672-4.
- Kozma K, Dömötör ZR, Csutak A, Szabó L, Hegyi P, Erőss B, et al. Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis. Sci Rep. 2022;12(1):14221.
- Patel U, Karp CL, Dubovy SR. Update on the Management of Ocular Surface Squamous Neoplasia. Curr Ophthalmol Rep. 2021;9(1):7-15.
- Cicinelli MV, Marchese A, Bandello F, Modorati G. Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence. Ophthalmol Ther. 2018;7(2):247-62.
- Mishra DK, Veena U, Kaliki S, Kethiri AR, Sangwan VS, Ali MH, et al. Differential Expression of Stem Cell Markers in Ocular Surface Squamous Neoplasia. PLoS One. 2016;11(9):e0161800.
- Rahimi F, Alipour F, Ghazizadeh Hashemi H, Hashemian MN, Mehrdad R. Topical mitomycin-C for treatment of partially-excised ocular surface squamous neoplasia. Arch Iran Med. 2009;12(1):55-9.
- Hegde SS, Pooja GS, Prakash DN, Dharwadkar S. A report on the outcome of topical mitomycin C as the primary treatment for ocular surface squamous neoplasia. J Med Sci Res. 2022; 10(2):82-6.
- Alvarez OP, Zein M, Galor A, Karp CL. Management of ocular surface squamous neoplasia: Bowman Club Lecture 2021. BMJ Open Ophthalmol. 2021;6(1):e000842.
- Yeoh CHY, Lee JJR, Lim BXH, Sundar G, Mehta JS, Chan ASY, et al. The Management of Ocular Surface Squamous Neoplasia (OSSN). Int J Mol Sci. 2022;24(1):713.
- Viani GA, Fendi LI. Adjuvant treatment or primary topical monotherapy for ocular surface squamous neoplasia: a systematic review. Arq Bras Oftalmol. 2017;80(2):131-6.
- Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol. 2010;94(10):1316-21.
- Hirst LW. Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: early resolution. Ophthalmology. 2007;114(5):976-82.
- Frucht-Pery J, Sugar J, Baum J, Sutphin JE, Pe'er J, Savir H, et al. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. Ophthalmology. 1997;104(12):2085-93.
- Ballalai PL, Erwenne CM, Martins MC, Lowen MS, Barros JN. Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia. Ophthalmic Plast Reconstr Surg. 2009;25(4):296-9.
- Al Bayyat G, Arreaza-Kaufman D, Venkateswaran N, Galor A, Karp CL. Update on pharmacotherapy for ocular surface squamous neoplasia. Eye Vis (Lond). 2019;6:24.
- Midena E, Frizziero L, Parrozzani R. Pharmacotherapy and Immunotherapy of Conjunctival Tumors. Asia Pac J Ophthalmol (Phila). 2017;6(2):121-31.
- Singh A, Jacques R, Rundle P, Mudhar HS, Slater D. Neoadjuvant topical mitomycin C chemotherapy for conjunctival and corneal intraepithelial neoplasia. Eye (London, England). 2006;20(9):1092-4.
- Giaconi JA, Karp CL. Current treatment options for conjunctival and corneal intraepithelial neoplasia. Ocul Surf. 2003;1(2):66-73.
- Siganos CS, Kozobolis VP, Christodoulakis EV. The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation. Cornea. 2002;21(1):12-6.
- Daniell M, Maini R, Tole D. Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Exp Ophthalmol. 2002;30(2):94-8.
- Carlos de Oliveira R, Wilson SE. Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK. Exp Eye Res. 2020;200:108218.
- Nassiri N, Farahangiz S, Rahnavardi M, Rahmani L, Nassiri N. Corneal endothelial cell injury induced by mitomycin-C in photorefractive keratectomy: nonrandomized controlled trial. J Cataract Refract Surg. 2008;34(6):902-8.
- Nassiri N, Sheibani K, Safi S, Haghnegahdar M, Nassiri S, Panahi N, et al. Alcohol-assisted debridement in PRK with intraoperative mitomycin C. Optom Vis Sci. 2014;91(9):1084-8.
- Wan Norliza WM, Raihan IS, Azwa JA, Ibrahim M. Scleral melting 16 years after pterygium excision with topical Mitomycin C adjuvant therapy. Cont Lens Anterior Eye. 2006;29(4):165-7.
- Cabourne E, Clarke JC, Schlottmann PG, Evans JR. Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery. Cochrane Database Syst Rev. 2015;2015(11):CD006259.
- Abstract Viewed: 37 times
- pdf Downloaded: 30 times
